Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab- or talquetamab-based triplets versus DRd in transplant-ineligible or non-transplant-intended newly diagnosed multiple myeloma
2022-000909-28Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of teclistamab, talquetamab, daratumumab, lenalidomide and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: PFS. Started Jul 2022; status: active.
02
Drugs
teclistamabtalquetamabdaratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-000909-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000909-28.